Trial Profile
A Phase I, Open Label, Multicenter, Dose Finding Study of IDH305 With Standard of Care in IDH1 Mutant Acute Myeloid Leukemia
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs IDH 305 (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 22 Nov 2018 Planned End Date changed from 22 Nov 2020 to 29 Nov 2016.
- 22 Nov 2018 Planned primary completion date changed from 1 Apr 2020 to 29 Nov 2016.
- 22 Nov 2018 Planned initiation date changed from 1 Aug 2016 to 26 Aug 2016.